Filtered By:
Drug: Medroxyprogesterone
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 487 results found since Jan 2013.
Contraindications to Hormonal Contraception Among Postpartum Women in Texas
CONCLUSION: Nearly one in five participants had a category 3 or 4 contraindication to combined hormonal contraception. Patients at higher risk for adverse birth outcomes are more likely to have contraindications. Clinicians should counsel on contraception and contraindications prenatally to facilitate the most informed postpartum decision.PMID:33831931 | DOI:10.1097/AOG.0000000000004347
Source: Obstetrics and Gynecology - April 8, 2021 Category: OBGYN Authors: Kate Coleman-Minahan Elizabeth J Ela Kari White Daniel Grossman Source Type: research
Method of Contraception and Risk of Ovarian Cancer Data
Ann Epidemiol. 2021 Apr 22:S1047-2797(21)00062-4. doi: 10.1016/j.annepidem.2021.04.006. Online ahead of print.ABSTRACTThe data presented here were obtained for New Zealand nationwide population-based case-control analysis undertaken to assess the association between ovarian cancer and depot medroxyprogesterone acetate (DMPA), intrauterine contraceptive devices (IUDs), and vasectomy of a woman's sexual partner [1]. Approval to conduct the research was obtained from Southern Health and Disability Ethics Committee (13/STH/26) and the University of Canterbury Ethics Committee (HEC 2013/08). Recruitment of participants and data...
Source: Annals of Epidemiology - April 25, 2021 Category: Epidemiology Authors: Jacqueline Chesang Ann Richardson John Potter Mary Sneyd Pat Coope Source Type: research
Association between Menopausal Hormone Therapy and Incidence of Psoriasis: A Secondary Analysis from the Women's Health Initiative Randomized Clinical Trials
Br J Dermatol. 2021 Apr 29. doi: 10.1111/bjd.20410. Online ahead of print.ABSTRACTEstrogen level fluctuations have been linked to psoriasis (1); however, the association between menopausal hormone therapy and risk of psoriasis is largely unexplored. We analyzed data from the Women's Health Initiative's (WHI) randomized controlled trials comparing conjugated equine estrogens (CEE) vs. placebo and CEE plus medroxyprogesterone acetate (MPA) vs. placebo to investigate the association between hormone therapy use and psoriasis.PMID:33913153 | DOI:10.1111/bjd.20410
Source: The British Journal of Dermatology - April 29, 2021 Category: Dermatology Authors: A A Chan J Noguti C T Yang S R Feldman R B Wallace A H Shadyab J E Manson A K Aragaki R T Chlebowski D J Lee Source Type: research
Method of Contraception and Risk of Ovarian Cancer Data
Ann Epidemiol. 2021 Apr 22:S1047-2797(21)00062-4. doi: 10.1016/j.annepidem.2021.04.006. Online ahead of print.ABSTRACTThe data presented here were obtained for New Zealand nationwide population-based case-control analysis undertaken to assess the association between ovarian cancer and depot medroxyprogesterone acetate (DMPA), intrauterine contraceptive devices (IUDs), and vasectomy of a woman's sexual partner [1]. Approval to conduct the research was obtained from Southern Health and Disability Ethics Committee (13/STH/26) and the University of Canterbury Ethics Committee (HEC 2013/08). Recruitment of participants and data...
Source: Annals of Epidemiology - April 25, 2021 Category: Epidemiology Authors: Jacqueline Chesang Ann Richardson John Potter Mary Sneyd Pat Coope Source Type: research
Association between Menopausal Hormone Therapy and Incidence of Psoriasis: A Secondary Analysis from the Women's Health Initiative Randomized Clinical Trials
Br J Dermatol. 2021 Apr 29. doi: 10.1111/bjd.20410. Online ahead of print.ABSTRACTEstrogen level fluctuations have been linked to psoriasis (1); however, the association between menopausal hormone therapy and risk of psoriasis is largely unexplored. We analyzed data from the Women's Health Initiative's (WHI) randomized controlled trials comparing conjugated equine estrogens (CEE) vs. placebo and CEE plus medroxyprogesterone acetate (MPA) vs. placebo to investigate the association between hormone therapy use and psoriasis.PMID:33913153 | DOI:10.1111/bjd.20410
Source: The British Journal of Dermatology - April 29, 2021 Category: Dermatology Authors: A A Chan J Noguti C T Yang S R Feldman R B Wallace A H Shadyab J E Manson A K Aragaki R T Chlebowski D J Lee Source Type: research
Method of Contraception and Risk of Ovarian Cancer Data
Ann Epidemiol. 2021 Apr 22:S1047-2797(21)00062-4. doi: 10.1016/j.annepidem.2021.04.006. Online ahead of print.ABSTRACTThe data presented here were obtained for New Zealand nationwide population-based case-control analysis undertaken to assess the association between ovarian cancer and depot medroxyprogesterone acetate (DMPA), intrauterine contraceptive devices (IUDs), and vasectomy of a woman's sexual partner [1]. Approval to conduct the research was obtained from Southern Health and Disability Ethics Committee (13/STH/26) and the University of Canterbury Ethics Committee (HEC 2013/08). Recruitment of participants and data...
Source: Annals of Epidemiology - April 25, 2021 Category: Epidemiology Authors: Jacqueline Chesang Ann Richardson John Potter Mary Sneyd Pat Coope Source Type: research
Association between Menopausal Hormone Therapy and Incidence of Psoriasis: A Secondary Analysis from the Women's Health Initiative Randomized Clinical Trials
Br J Dermatol. 2021 Apr 29. doi: 10.1111/bjd.20410. Online ahead of print.ABSTRACTEstrogen level fluctuations have been linked to psoriasis (1); however, the association between menopausal hormone therapy and risk of psoriasis is largely unexplored. We analyzed data from the Women's Health Initiative's (WHI) randomized controlled trials comparing conjugated equine estrogens (CEE) vs. placebo and CEE plus medroxyprogesterone acetate (MPA) vs. placebo to investigate the association between hormone therapy use and psoriasis.PMID:33913153 | DOI:10.1111/bjd.20410
Source: The British Journal of Dermatology - April 29, 2021 Category: Dermatology Authors: A A Chan J Noguti C T Yang S R Feldman R B Wallace A H Shadyab J E Manson A K Aragaki R T Chlebowski D J Lee Source Type: research
Estrogen-induced gallstone pancreatitis in a transgender female
CONCLUSION: Estrogen is a cornerstone of gender-affirming hormone therapy used by transgender women; however, in addition to its role in gender identity confirmation, estrogen can result in drug-induced pancreatitis.PMID:33948625 | DOI:10.1093/ajhp/zxab190
Source: American Journal of Health-System Pharmacy : AJHP - May 5, 2021 Category: Drugs & Pharmacology Authors: Emily Freier Lynn Kassel Joel Rand Bhavana Chinnakotla Source Type: research
Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):739-743. doi: 10.15585/mmwr.mm7020a2.ABSTRACTU.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR), adapted by CDC from global guidance developed by the World Health Organization (WHO), provides evidence-based guidance on contraceptive use for U.S. health care providers (1). During January-February, 2021, CDC evaluated the 2019 WHO recommendation on self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (2). CDC adopted the WHO recommendation on the basis of moderate-certainty evidence that self-administered DMPA-SC is safe and effective, a...
Source: MMWR Morb Mortal Wkl... - May 20, 2021 Category: Epidemiology Authors: Kathryn M Curtis Antoinette Nguyen Jennifer A Reeves Elizabeth A Clark Suzanne G Folger Maura K Whiteman Source Type: research
